<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972462</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-12G-4/US</org_study_id>
    <nct_id>NCT03972462</nct_id>
  </id_info>
  <brief_title>NPC-12G Gel 0.2% Sirolimus PK Bridging Study</brief_title>
  <official_title>Open-label, Fixed-sequence, Two-period Comparative Bioavailability Study of Sirolimus From Topical Application of NPC-12G Gel to Oral Rapamune® Following Single Administration in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to describe the relative systemic bioavailability of topical and oral
      sirolimus formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Actual">June 17, 2019</completion_date>
  <primary_completion_date type="Actual">June 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-48</measure>
    <time_frame>Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Sampling: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bioavailability Study</condition>
  <arm_group>
    <arm_group_label>NPC-12G Gel 0.2% (Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamune Tablet (Period 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapamune® (sirolimus) 2 mg tablet for oral dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-12G Gel 0.2%</intervention_name>
    <description>Period 1</description>
    <arm_group_label>NPC-12G Gel 0.2% (Period 1)</arm_group_label>
    <other_name>2 mg of sirolimus in 1 g of gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune® 2 mg tablet</intervention_name>
    <description>Period 2</description>
    <arm_group_label>Rapamune Tablet (Period 2)</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, non-smoker (no use within 3 months prior to screening), ≥ 18 and ≤ 65
             years of age, with BMI &gt; 18.5 and &lt; 30.0 kg/m2 and body weight ≥ 50.0 kg for males and
             ≥ 45.0 kg for females

          -  Females of childbearing potential who are sexually active with a male partner must be
             willing to use one of acceptable contraceptive method throughout the study and for 12
             weeks after the last study drug administration

        Exclusion Criteria

          -  Any sign of eczema/dermatitis, skin lesion, wound, or infection at the application
             site, or any other conditions that would prevent a safe application of the gel
             formulation.

          -  Laser or surgery at the gel application site within 2 weeks before the gel
             application.

          -  Positive alcohol breath test, urine drug screen or urine cotinine test at
             screeningation

          -  History of allergic reactions or hypersensitivity to sirolimus, sirolimus derivatives,
             or excipient of NPC-12G Gel

          -  Use of any drugs known to induce or inhibit CYP3A4 metabolism within 30 days prior to
             the first study drug administration

          -  Positive pregnancy test at screening

          -  Breast-feeding subject

          -  History of active tuberculosis or exposure to endemic areas within 8 weeks prior to
             QuantiFERON®-TB testing performed at screening

          -  Positive QuantiFERON®-TB test with positive chest X-ray, indicating possible
             tuberculosis infection

          -  Immunization with a live attenuated vaccine within 1 month prior to dosing or planned
             vaccination during the study and up to 3 weeks after the last study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>InVentiv Health Clinical Research Services LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

